Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add-on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care (LIRA-PRIME).
Unger J, Allison DC, Kaltoft M, Lakkole K, Panda JK, Ramesh C, Sargin M, Smolyarchuk E, Twine M, Wolthers B, Yarimbas G, Zoghbi M; LIRA-PRIME investigators. Unger J, et al. Among authors: wolthers b. Diabetes Obes Metab. 2022 Feb;24(2):204-211. doi: 10.1111/dom.14566. Epub 2021 Oct 18. Diabetes Obes Metab. 2022. PMID: 34622567 Free PMC article. Clinical Trial.
Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN-6 cardiovascular outcomes trials.
Kahkoska AR, Geybels MS, Klein KR, Kreiner FF, Marx N, Nauck MA, Pratley RE, Wolthers BO, Buse JB. Kahkoska AR, et al. Among authors: wolthers bo. Diabetes Obes Metab. 2020 Sep;22(9):1537-1547. doi: 10.1111/dom.14063. Epub 2020 May 18. Diabetes Obes Metab. 2020. PMID: 32314525 Free PMC article.
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.
Shaman AM, Bain SC, Bakris GL, Buse JB, Idorn T, Mahaffey KW, Mann JFE, Nauck MA, Rasmussen S, Rossing P, Wolthers B, Zinman B, Perkovic V. Shaman AM, et al. Among authors: wolthers b. Circulation. 2022 Feb 22;145(8):575-585. doi: 10.1161/CIRCULATIONAHA.121.055459. Epub 2021 Dec 14. Circulation. 2022. PMID: 34903039 Free PMC article. Clinical Trial.
International consensus definitions of clinical trial outcomes for kidney failure: 2020.
Levin A, Agarwal R, Herrington WG, Heerspink HL, Mann JFE, Shahinfar S, Tuttle KR, Donner JA, Jha V, Nangaku M, de Zeeuw D, Jardine MJ, Mahaffey KW, Thompson AM, Beaucage M, Chong K, Roberts GV, Sunwold D, Vorster H, Warren M, Damster S, Malik C, Perkovic V; participant authors of the International Society of Nephrology’s 1st International Consensus Meeting on Defining Kidney Failure in Clinical Trials. Levin A, et al. Kidney Int. 2020 Oct;98(4):849-859. doi: 10.1016/j.kint.2020.07.013. Kidney Int. 2020. PMID: 32998816 Free article.
Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study.
Lynggaard LS, Rank CU, Hansen SN, Gottschalk Højfeldt S, Henriksen LT, Jarvis KB, Ranta S, Niinimäki R, Harila-Saari A, Wolthers BO, Frandsen TL, Heyman M, Schmiegelow K, Albertsen BK. Lynggaard LS, et al. Among authors: wolthers bo. Blood Adv. 2022 Jan 11;6(1):138-147. doi: 10.1182/bloodadvances.2021005631. Blood Adv. 2022. PMID: 34625787 Free PMC article.
Dyslipidemia at diagnosis of childhood acute lymphoblastic leukemia.
Mogensen PR, Grell K, Schmiegelow K, Overgaard UM, Wolthers BO, Mogensen SS, Vaag A, Frandsen TL. Mogensen PR, et al. PLoS One. 2020 Apr 6;15(4):e0231209. doi: 10.1371/journal.pone.0231209. eCollection 2020. PLoS One. 2020. PMID: 32251440 Free PMC article.
174 results